Drug Database
Back to search

Poland· PL-100541022

Opdivo

A nivolumab product containing nivolumabum, registered in Poland by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 13 of our 19 countries.

ATC L01FF01

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedOpdivoATCL01FF01REGISTER NO.PL-100541022PACKS LISTED2CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about nivolumabumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Nivolumab is registered in 13 of 19 countries.

Countries holding a registration under ATC L01FF01 (nivolumab), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 8 of them publish a price we can compare per daily dose
Search nivolumab products by name

Nivolumab · ATC L01FF01

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Nivolumabum
Manufacturer
Bristol-Myers Squibb Pharma EEIG
Country
Poland (PL)
ATC code
L01FF01
ATC class
Nivolumab
Defined daily dose
17.1 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 2

  • gtin
    08027950802371
  • gtin
    04150205195141

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

22 interactions on record for nivolumab.

Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check nivolumab against other medicinesHow interaction checks work

Nivolumab · interactions on record

22 records

  • 3 severe
  • 19 moderate

Most severe, free to view

  • ThalidomideL04AX02severe
  • LenalidomideL04AX04severe
  • PomalidomideL04AX06severe
  • PrednisoloneA07EA01moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Nivolumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All nivolumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Opdivo
  • Liechtenstein · Opdivo
  • Norway · Opdivo

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f5a2a5cc-f185-47c6-9412-2a4f83e3f80a
GET /v1/drugs/f5a2a5cc-f185-47c6-9412-2a4f83e3f80a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań",
  "source": "urpl",
  "strength": "300 mg",
  "packaging": "08027950802371 ¦ Rpz ¦ EU/1/15/1014/006 ¦ 167612\n1 fiol. 2,5 ml\n¦ UR/Z/4c/216/26 - 04150205195141",
  "substance": "Nivolumabum 300 mg",
  "common_name": "Nivolumabum",
  "pl_product_id": "100541022",
  "pozwolenie_nr": null,
  "auth_procedure": "CEN",
  "authorisation_validity": null
}
API referenceMCP serverPlans

See everything about nivolumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console